Richard Daniell sold $548k of TEVA
EVP, Europe Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD. 17,295 shares at an average of $31.67, traded Mar 5, 2026, filed Mar 9, 2026.
Score components
- +15RoleOfficer
- +19Trade size$548k at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-098512, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | MOption exercise Ordinary Shares10b5-1 | +17,295 | - | - | 103,050 | Mar 9, 2026 |
| Mar 5, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -17,295 | $31.67 | $548k | 85,755 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Restricted Share Unitsderivative10b5-1 | -17,295 | $0.00 | $0 | 51,887 | Mar 9, 2026 |
Related signals
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $14M 367,600 shares | -100% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $285k 7,342 shares | -46% | |
| 8Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Christine Fox EVP, U.S. Commercial | $251k 7,924 shares | -9% | |
| 25Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $634k 20,025 shares | -2% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell EVP, Europe Commercial | $3.0M 91,345 shares | -58% | |
| 14Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Christine Fox EVP, U.S. Commercial | $295k 9,098 shares | -11% | |
| 27Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $759k 23,393 shares | -2% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell EVP, Europe Commercial | $4.2M 128,985 shares | -117% | |
| 50Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $14M 442,935 shares | -66% | |
| 35Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $15M 447,778 shares | -103% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.